Literature DB >> 9226193

Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease.

R Selby, E Nisbet-Brown, R K Basran, L Chang, N F Olivieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9226193

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Induction of fetal hemoglobin by propionic and butyric acid derivatives: correlations between chemical structure and potency of Hb F induction.

Authors:  Effie Liakopoulou; Qiliang Li; George Stamatoyannopoulos
Journal:  Blood Cells Mol Dis       Date:  2002 Jul-Aug       Impact factor: 3.039

2.  Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.

Authors:  Maureen M Okam; Erica B Esrick; Elyse Mandell; Federico Campigotto; Donna S Neuberg; Benjamin L Ebert
Journal:  Blood       Date:  2015-06-04       Impact factor: 22.113

Review 3.  Valproic Acid: second generation.

Authors:  Meir Bialer; Boris Yagen
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

4.  Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET.

Authors:  Sung Won Kim; Jacob M Hooker; Nicola Otto; Khaing Win; Lisa Muench; Colleen Shea; Pauline Carter; Payton King; Alicia E Reid; Nora D Volkow; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2013-07-29       Impact factor: 2.408

5.  The effect of hydroxyurea on vasculopathy in a child with sickle cell disease.

Authors:  Kathleen J Helton; Winfred C Wang; Lynn W Wynn; Raja B Khan; R Grant Steen
Journal:  AJNR Am J Neuroradiol       Date:  2002 Nov-Dec       Impact factor: 3.825

6.  Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma.

Authors:  Johannes E A Wolff; Christof Kramm; Rolf-Dieter Kortmann; Torsten Pietsch; Stefan Rutkowski; Norbert Jorch; Astrid Gnekow; Pablo Hernáiz Driever
Journal:  J Neurooncol       Date:  2008-08-05       Impact factor: 4.130

7.  The effect of histone deacetylase inhibitors on AHSP expression.

Authors:  Mohammad Ali Okhovat; Katayoun Ziari; Reza Ranjbaran; Negin Nikouyan
Journal:  PLoS One       Date:  2018-02-01       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.